Eron Kelly appointed as chief executive officer; Dr. Jeff Elton, founding CEO, to transition to vice chairman of the board

CAMBRIDGE, Mass.: ConcertAI, a leader in oncology generative and agentic AI SaaS and multi-modal data solutions for healthcare and life sciences, announced today that Eron Kelly has been appointed Chief Executive Officer. Kelly succeeds Dr. Jeff Elton, who will transition from his role as CEO to Vice Chairman of the company.

Kelly comes to ConcertAI from Inovalon, a cloud-based healthcare SaaS provider, where he has served as President since 2021. During his tenure at Inovalon, he drove the company’s transformation into a pure-play cloud-based SaaS and DaaS provider while bringing new AI solutions into each business unit and achieving double digit growth. Prior to Inovalon, he spent more than 20 years bringing new cloud products to market at both Amazon Web Services (AWS) and Microsoft. At AWS, he led worldwide product marketing for more than 40 services across six major categories that grew 250% during his tenure to $40 billion in revenue, and at Microsoft, he led the creation of Office 365 and helped grow it into a $13 billion business during his time through leadership roles in product management, sales and marketing. His appointment reinforces ConcertAI's commitment to providing innovation and technological leadership in enterprise AI.

“I am honored to join ConcertAI at such a pivotal moment,” said Kelly. “The company has built an exceptional foundation of data, AI technologies and customer relationships. I look forward to working with the talented team here to accelerate our product roadmap and continue to deliver solutions that create measurable value for our customers.”

Since the company’s founding, Jeff Elton successfully established ConcertAI as a leader in AI technologies and multi-modal clinical data at population scale, aligning suites of solutions across the needs of biomedical innovators and healthcare providers. He successfully oversaw the acquisitions of TeraRecon’s imaging technology and CancerLinQ’s vast network of oncology clinics. Over the last three years, the company has established major collaborations and partnerships with NVIDIA and major molecular diagnostics companies. Together, these significantly advanced the enterprise value of the company and enabled the company to be among the first among peers to achieve being EBITDA-positive. In his new role as Vice Chairman of the Board, he will continue to be a key strategist and industry thought leader for ConcertAI, supporting the company's next phase of growth and development through transformational partnerships and other initiatives.

“Eron’s appointment comes at an exciting time for ConcertAI as we continue to advance our AI innovation agenda,” said Dr. Romesh Wadhwani, Executive Chairman. “His exceptional product leadership experience and proven track record of driving growth at enterprise technology companies make him the ideal leader to accelerate our next phase of development. Jeff has built an extraordinary foundation, and I'm confident that under Eron's leadership, ConcertAI will further strengthen our position as a leader in enterprise AI technologies while delivering even greater value to our life sciences and healthcare customers. This leadership transition represents a strategic evolution in our company's growth journey.”

“I am incredibly proud of what we have accomplished at ConcertAI and excited to have Eron as the leader for the next phase of the company’s growth,” said Elton. “These past 18 months have confirmed that our company and the industry’s future are going to be driven by new generative and agentic AI solutions. Eron brings the product expertise and vision for AI innovation that will help us capitalize on the tremendous market opportunities ahead while building on our strong foundation.”

About ConcertAI

ConcertAI is the leader in predictive and generative AI SaaS and real-world data research solutions for healthcare and life sciences. Our mission is to accelerate insights and outcomes for patients through research-ready data, CARAai™ technologies, and scientific expertise in partnership with over 46 leading biomedical innovators, 2,000 healthcare providers, and medical societies. TeraRecon provides advanced radiological image visualizations and clinical AI decision augmentation solutions for MRI and CT. CancerLinQ® is an initiative of ConcertAI, providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified® quality solutions and SmartLinQ™ analytic services. Headquartered in Cambridge, Massachusetts, ConcertAI has offices in Bangalore, Frankfurt, Philadelphia, Raleigh-Durham, and Tokyo. For more information, visit us at concertai.com.

Fonte: Business Wire